Investment Thesis
CNS Pharmaceuticals is a severely distressed pre-revenue biotech company with negative operating cash flow of -4.6M, stockholders' equity of only 70.7K, and just 3M in cash against annual burn rates suggesting <1 year runway. The company is financially insolvent on a book value basis with liquidity ratios below 1.0, facing imminent capital depletion absent significant financing or revenue generation.
Strengths
- Minimal long-term debt burden reduces leverage risk
- EPS loss improvement trend (-7.30 vs prior -9.68) shows cost control
- 3M cash reserve provides short-term liquidity buffer
Risks
- Operating cash burn of -4.6M annually against 3M cash reserves indicates <1 year runway
- Stockholders equity of 70.7K indicates near-complete capital depletion
- Current ratio of 0.89x signals inability to cover short-term obligations
- Zero revenue generation with -4.9M net losses unsustainable long-term
- Negative ROE (-6982.6%) and ROA (-106.1%) demonstrate value destruction
Key Metrics to Watch
- Monthly burn rate and updated cash runway calculations
- Financing announcements or capital raise events
- Clinical trial progress and regulatory milestones for drug candidates
Financial Metrics
Revenue
N/A
Net Income
-4.9M
EPS (Diluted)
$-7.30
Free Cash Flow
-4.7M
Total Assets
4.7M
Cash
3.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-6,982.6%
ROA
-106.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.89x
Quick Ratio
0.89x
Debt/Equity
0.00x
Debt/Assets
98.5%
Interest Coverage
-750.97x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:04:15.169231 |
Data as of: 2026-03-31 |
Powered by Claude AI